This session focuses on the essential legal and funding strategies for early-stage biotech startups, emphasizing the importance of intellectual property (IP) management, legal structures, and the role of due diligence in attracting investors. The panel discusses common pitfalls, the significance of contracts, and the challenges of commercializing university IP. They also explore the timing of freedom to operate studies and the evolving landscape of biotech investment.

For this session, the featured guests were:

1. Chyreene Truluck – Partner at Spoor & Fisher, specializing in intellectual property (IP) law and IP management strategies.
2. Dr Vuyisile Phehane – Executive Manager of UJInvnt Pty Ltd, the Intellectual Property (IP) commercialization company of the University of Johannesburg, South Africa
3. Lucie Arntz – Senior Associate at Hogan Lovells, one of the world's top law firms with 2,532 lawyers working from 51 destinations around the globe.

Takeaways

• Intellectual property is crucial for competitive advantage in biotech.
• Startups should consider outsourcing legal services to manage costs.
• Choosing the right legal structure is vital for biotech startups.
• Understanding IP management is essential for attracting funding.
• Collaboration agreements must clearly define IP ownership and rights.
• Due diligence is critical for investors assessing biotech startups.
• Patents provide public protection, while trade secrets require confidentiality.
• Commercialization often requires significant investment beyond R&D costs.
• Startups should be open to acquisition opportunities.
• Timing and strategic planning are key to successful biotech ventures.